# OnCo record paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017" ;
  schema:name "Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial"@en ;
  schema:alternateName "H10"@en, "André 2017"@en, "EORTC H10"@en ;
  schema:description "In early Hodgkin lymphoma, switching to more intensive chemotherapy when the scan was still positive raised five-year freedom from progression from 77 to 91 per cent."@en ;
  schema:url <https://onco.cc/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2016.68.6394>, <https://pubmed.ncbi.nlm.nih.gov/28291393/>, <https://europepmc.org/article/MED/28291393> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1200/JCO.2016.68.6394> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "André MPE, Girinsky T, Federico M, et al." ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/radiation/>, <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/imaging/> ;
  onco:technologies <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/prednisone/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/non-inferiority/> ;
  onco:trials <https://onco.cc/trials/eortc-h10/>, <https://onco.cc/trials/hd16/>, <https://onco.cc/trials/radar-hodgkin/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/jco/> .